Overactive Bladder SyndromePhase 3NCT00546637
Fesoterodine "add-on" Male Overactive Bladder Study
A Phase 3 study testing Fesoterodine in people with Overactive Bladder Syndrome, run by Pfizer at 137 sites in 19 countries.
Trial summary
To evaluate the efficacy and safety of fesoterodine on overactive bladder symptom improvement when added to ongoing alpha blocker treatment. Read more about this study
- Who is it for?
- Ages 40 years and older, men only
- Conditions the study is for
- Overactive Bladder Syndrome
- What is being tested?
- Fesoterodine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 947 participants
- Where
- 137 sitesin 19 countries
- Study dates
- Nov 2007to Feb 2009
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- Men only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Men aged 40 years and above.
- On a stable and well-tolerated dose of an alpha-blocker prescribed for LUTS for at least 6 weeks prior to screening (Visit 1).
- Persistent symptoms of OAB with urinary frequency >=8 times/24 hours and micturition-related urgency episodes >=3 episode/24 hours.
Who cannot join
- Contraindication to fesoterodine (antimuscarinics).
- Previous history of acute urinary retention requiring catheterization or severe voiding difficulties in the judgment of the investigator, prior to baseline.
- Unable to follow the study procedures, including completion of self-administered bladder diary and patient reported outcome questionnaires.
Trial locations and contacts
137 sites in 19 countries.
137 sites in 19 countries
United States62 sites
Pfizer Investigational Site
Albany, New York, 12208
Pfizer Investigational Site
Aurora, Colorado, 80012
Pfizer Investigational Site
Austin, Texas, 78705
Pfizer Investigational Site
Austin, Texas, 78759
Pfizer Investigational Site
Bala-Cynwyd, Pennsylvania, 19004
Pfizer Investigational Site
Baltimore, Maryland, 21204
Pfizer Investigational Site
Bethany, Oklahoma, 73008
Pfizer Investigational Site
Birmingham, Alabama, 35209
Pfizer Investigational Site
Camp Hill, Pennsylvania, 17011
Pfizer Investigational Site
Charleston, South Carolina, 29425
Pfizer Investigational Site
Cincinnati, Ohio, 45242
Pfizer Investigational Site
Columbus, Ohio, 43214
Pfizer Investigational Site
Columbus, Ohio, 43220
Pfizer Investigational Site
Denver, Colorado, 80211
Pfizer Investigational Site
Des Moines, Iowa, 50309
Pfizer Investigational Site
Dunwoody, Georgia, 30338
Pfizer Investigational Site
Durham, North Carolina, 27710
Pfizer Investigational Site
Evansville, Indiana, 47713
Pfizer Investigational Site
Fargo, North Dakota, 58103
Pfizer Investigational Site
Fargo, North Dakota, 58104
Pfizer Investigational Site
Flint, Michigan, 48507
Pfizer Investigational Site
Garden City, New York, 11530
Pfizer Investigational Site
Gilbert, Arizona, 85234
Pfizer Investigational Site
Gilbert, Arizona, 85295
Pfizer Investigational Site
Greensboro, North Carolina, 27403
Pfizer Investigational Site
Greer, South Carolina, 29650
Pfizer Investigational Site
Houston, Texas, 77024
Pfizer Investigational Site
Iowa City, Iowa, 52242
Pfizer Investigational Site
Jeffersonville, Indiana, 47130
Pfizer Investigational Site
Jupiter, Florida, 33458
Pfizer Investigational Site
Kingston, New York, 12401
Pfizer Investigational Site
La Mesa, California, 91942
Pfizer Investigational Site
Litchfield Park, Arizona, 85340
Pfizer Investigational Site
Madison, Wisconsin, 53715
Pfizer Investigational Site
Mesa, Arizona, 85210
Pfizer Investigational Site
Milwaukee, Wisconsin, 53209
Pfizer Investigational Site
Minneapolis, Minnesota, 55455
Pfizer Investigational Site
New York, New York, 10016
Pfizer Investigational Site
Newburgh, Indiana, 47630
Pfizer Investigational Site
Newport Beach, California, 92660
Pfizer Investigational Site
Omaha, Nebraska, 68114
Pfizer Investigational Site
Orange City, Florida, 32763
Pfizer Investigational Site
Owings Mills, Maryland, 21117
Pfizer Investigational Site
Phoenix, Arizona, 85021
Pfizer Investigational Site
Pittsburgh, Pennsylvania, 15213
Pfizer Investigational Site
Portland, Oregon, 97239
Pfizer Investigational Site
Poughkeepsie, New York, 12601
Pfizer Investigational Site
Saint Clair Shores, Michigan, 48081
Pfizer Investigational Site
San Bernardino, California, 92404
Pfizer Investigational Site
San Diego, California, 92103-6204
Pfizer Investigational Site
San Diego, California, 92103
Pfizer Investigational Site
Sewell, New Jersey, 08080
Pfizer Investigational Site
Syracuse, New York, 13210
Pfizer Investigational Site
Tacoma, Washington, 98431-1100
Pfizer Investigational Site
Troy, Michigan, 48084
Pfizer Investigational Site
Tucson, Arizona, 85712
Pfizer Investigational Site
Utica, Michigan, 48081
Pfizer Investigational Site
Watertown, Massachusetts, 02472
Pfizer Investigational Site
West Bloomfield, Michigan, 48322
Pfizer Investigational Site
West Bloomfield, Michigan, 48323
Pfizer Investigational Site
West Palm Beach, Florida, 33401
Pfizer Investigational Site
Williamsville, New York, 14221
Canada9 sites
Pfizer Investigational Site
Barrie, Ontario, L4M 7G1
Pfizer Investigational Site
Chicoutimi, Quebec, G7H 4A3
Pfizer Investigational Site
North Bay, Ontario, P1B 7K8
Pfizer Investigational Site
Pointe-Claire, Quebec, H9R 4S3
Pfizer Investigational Site
Sherbrooke, Quebec, J1H 5N4
Pfizer Investigational Site
Toronto, Ontario, M5T 2S8
Pfizer Investigational Site
Toronto, Ontario, M6A 3B5
Pfizer Investigational Site
Victoria, British Columbia, V8T 5G1
Pfizer Investigational Site
Winnipeg, Manitoba, R3A 1R9
Germany8 sites
Pfizer Investigational Site
Berlin, 12627
Pfizer Investigational Site
Frankfurt, 60596
Pfizer Investigational Site
Göttingen, 37073
Pfizer Investigational Site
Hagenow, 19230
Pfizer Investigational Site
Lauenburg, 21481
Pfizer Investigational Site
Leipzig, 04109
Pfizer Investigational Site
Oberursel, 61440
Pfizer Investigational Site
Wiesbaden, 65198
Brazil6 sites
Pfizer Investigational Site
Campos do Jordão, São Paulo, 12460-000
Pfizer Investigational Site
Curitiba, Paraná, 80060-900
Pfizer Investigational Site
Porto Alegre, Rio Grande do Sul, 90610-000
Pfizer Investigational Site
Rio de Janeiro, Rio de Janeiro, CEP 20551-030
Pfizer Investigational Site
Salvador, Estado de Bahia, 40420-000
Pfizer Investigational Site
São Paulo, São Paulo, 04262-000
Philippines6 sites
Pfizer Investigational Site
Bacolod City, 6100
Pfizer Investigational Site
Cebu City, Cebu, 6000
Pfizer Investigational Site
Makati City, 1200
Pfizer Investigational Site
Manila, 1000
Pfizer Investigational Site
Manila, 1008
Pfizer Investigational Site
Quezon City, Philippines, 1113
Poland6 sites
Pfizer Investigational Site
Bialystok, 15-232
Pfizer Investigational Site
Gdansk, 80-402
Pfizer Investigational Site
Gdansk, 80-462
Pfizer Investigational Site
Lodz, 93-338
Pfizer Investigational Site
Mysłowice, 41-400
Pfizer Investigational Site
Wroclaw, 51-124
Slovakia5 sites
Pfizer Investigational Site
Banská Bystrica, 974 01
Pfizer Investigational Site
Bratislava, Slovakia, 833 05
Pfizer Investigational Site
Martin, Slovakia, 036 59
Pfizer Investigational Site
Piešťany, Slovakia, 921 01
Pfizer Investigational Site
Skalica, 909 82
Sweden5 sites
Pfizer Investigational Site
Borås, 503 32
Pfizer Investigational Site
Jönköping, 554 66
Pfizer Investigational Site
Skövde, 541 30
Pfizer Investigational Site
Stockholm, 117 94
Pfizer Investigational Site
Stockholm, 141 86
India4 sites
Pfizer Investigational Site
Lucknow, Uttar Pradesh, 226003
Pfizer Investigational Site
Lucknow, Uttar Pradesh, 226014
Pfizer Investigational Site
Ludhiana, Punjab, 141008
Pfizer Investigational Site
New Delhi, New Delhi, 110029
South Korea4 sites
Pfizer Investigational Site
Bucheon-si, Gyunggi-do, 420-717
Pfizer Investigational Site
Pusan, 602-739
Pfizer Investigational Site
Seoul, 135-710
Pfizer Investigational Site
Seoul, 135-720
Belgium3 sites
Pfizer Investigational Site
Antwerp, 2020
Pfizer Investigational Site
Edegem, B-2650
Pfizer Investigational Site
Leuven, B-3000
Greece3 sites
Pfizer Investigational Site
Ioannina, Ipiros, 45 110
Pfizer Investigational Site
Pátrai, 26500
Pfizer Investigational Site
Thessaloniki, 56403
Netherlands3 sites
Pfizer Investigational Site
Roermond, 6043 CV
Pfizer Investigational Site
Tilburg, 5022 GC
Pfizer Investigational Site
Zutphen, 7207 BA
Spain3 sites
Pfizer Investigational Site
Getafe, Madrid, 28905
Pfizer Investigational Site
Manacor, Palma de Mallorca, 07500
Pfizer Investigational Site
Martorell, Barcelona, 08760
Colombia2 sites
Pfizer Investigational Site
Bogota, Cundinamarca, 0000
Pfizer Investigational Site
Medellín, Antioquia, 0000
Malaysia2 sites
Pfizer Investigational Site
Kuching, Sarawak, 93050
Pfizer Investigational Site
Kuching, Sarawak, 93586
Norway2 sites
Pfizer Investigational Site
Bodø, 8087
Pfizer Investigational Site
Oslo, NO-0257
Singapore2 sites
Pfizer Investigational Site
Singapore, Singapore, 169608
Pfizer Investigational Site
Singapore, Singapore, 308433
Thailand2 sites
Pfizer Investigational Site
Amphoe Mueang, Chiang Mai, 50200
Pfizer Investigational Site
Ratchathewi, Bangkok, 10400
About this study
Official title: A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Fesoterodine As An "Add-On" Therapy In Men With Persistent Overactive Bladder Symptoms Under Monotherapy Of Alpha Blocker For Lower Urinary Tract Symptoms.
To evaluate the efficacy and safety of fesoterodine on overactive bladder symptom improvement when added to ongoing alpha blocker treatment.
- Conditions
- Overactive Bladder Syndrome
- Being tested
- Fesoterodine, Placebo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FesoterodineDrug
Fesoterodine 4mg or 8mg
PlaceboDrug
Placebo
| Study group | Role | What they receive |
|---|---|---|
| Fesoterodine 4mg or 8mg | Experimental | Not described Receives: Drug: Fesoterodine |
| Placebo | Placebo comparator | Not described Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Numerical Change From Baseline in Micturition-Related Urgency Episodes Per 24 Hours at Week 12
The mean number of micturition-related urgency episodes per 24 hours was calculated as the total number of micturitions with USS Scale >= 3 divided by the total number of days that diary data was collected at that visit. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.
Measured: Baseline, Week 12
Secondary outcomes (33)
Numerical Change From Baseline in Micturition-Related Urgency Episodes Per 24 Hours at Week 4
The mean number of micturition-related urgency episodes per 24 hours was calculated as the total number of micturitions with USS Scale >= 3 divided by the total number of days that diary data was collected at that visit. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.
Measured: Baseline, Week 4
Percentage Change From Baseline in Micturition-Related Urgency Episodes Per 24 Hours at Week 4 and 12
Micturition-related urgency episodes per 24 hours were defined as those with USS Scale rating of >= 3 marked for the corresponding micturition in the diary. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine. The percentage change at Week 4 or 12 was calculated as:
100* (Micturition-Related Urgency Episodes at Week 4 or 12 - Baseline)/Baseline
Measured: Baseline, Week 4 and 12
Numerical Change From Baseline in Micturitions Per 24 Hours at Week 4 and 12
All micturitions with USS rating 1 to 5. USS rating: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine. The mean number of micturitions per 24 hours was calculated as the total number of micturitions divided by the total number of diary days collected at that visit. Numeric change of micturitions per 24 hours at Week 4 and 12 relative to Baseline.
Measured: Baseline, Week 4 and 12
Percentage Change From Baseline in Micturitions Per 24 Hours at Week 4 and 12
All micturitions with USS rating 1 to 5. USS rating: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine. The percentage change at Week 4 or 12 was calculated as: 100* (Micturitions at Week 4 or 12 - Baseline)/Baseline
Measured: Baseline, Week 4 and 12
Numerical Change From Baseline in Nocturnal Micturitions Per 24 Hours at Week 4 and 12
Nocturnal micturitions were defined as micturitions with USS rating 1-5 that occurred between the time the subject went to bed and the time he or she arose to start the next day. USS rating: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine. The mean number of nocturnal micturitions per 24 hours was calculated as the total number of nocturnal micturitions divided by the total number of diary days collected at that visit.
Measured: Baseline, Week 4 and 12
Percentage Change From Baseline in Nocturnal Micturitions Per 24 Hours at Week 4 and 12
Nocturnal micturitions were defined as micturitions with USS rating 1-5 that occurred between the time the subject went to bed and the time he or she arose to start the next day. USS rating: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine. The percentage change at Week 4 or 12 was calculated as: 100* (Nocturnal micturitions at Week 4 or 12 - Baseline)/Baseline
Measured: Baseline, Week 4 and 12
Numerical Change From Baseline in Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 4 and 12
UUI episodes were defined as those micturitions with USS rating of 5 in the diary in subjects with UUI at baseline. USS rating 5: Unable to hold; leak urine.
Measured: Baseline, Week 4 and Week 12
Percentage Change From Baseline in UUI Episodes Per 24 Hours at Week 4 and 12
UUI episodes are defined as those micturitions with a USS rating of 5 in the bladder diary in subjects with UUI at baseline. USS rating 5: Unable to hold; leak urine. The percentage change at Week 4 or 12 was calculated as: 100* (UUI Episodes at Week 4 or 12 - Baseline)/Baseline
Measured: Baseline, Week 4 and 12
Numerical Change From Baseline in Severe Micturition-Related Urgency Episodes Per 24 Hours at Week 4 and 12
Severe micturition related urgency episodes were defined as those micturitions with USS rating >=4 marked for the corresponding micturition in the diary. USS: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.
Measured: Baseline, Week 4 and 12
Percentage Change From Baseline in Severe Micturition-Related Urgency Episodes Per 24 Hours at Week 4 and 12
Severe micturition-related urgency episodes are defined as those with a USS rating ≥4 marked for the corresponding micturition in the bladder diary. USS rating: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine. The percentage change at Week 4 or 12 was calculated as: 100* (Severe Micturition-Related Urgency Episodes at Week 4 or 12 - Baseline)/Baseline
Measured: Baseline, Week 4 and 12
Numerical Change From Baseline in Nocturnal Micturition-Related Urgency Episodes Per 24 Hours at Week 4 and 12
Nocturnal micturition-related urgency episodes were defined as micturition-related urgency episodes with USS ratings 3-5 that occurred between the time the subject went to bed and the time he or she arose to start the next day. USS rating: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.
Measured: Baseline, Week 4 and 12
Percentage Change From Baseline in Nocturnal Micturition-Related Urgency Episodes Per 24 Hours at Week 4 and 12
Nocturnal micturition-related urgency episodes were defined as micturition-related urgency episodes with USS ratings 3-5 that occurred between the time the subject went to bed and the time he or she arose to start the next day. USS rating: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine. The percentage change at Week 4 or 12 was calculated as: 100* (Nocturnal Micturition-Related Urgency Episodes at Week 4 or 12 - Baseline)/Baseline
Measured: Baseline, Week 4 and 12
Numerical Change From Baseline in Urinary Sensation Scale (USS) Sum Rating Per 24 Hours at Week 4 and 12
The USS sum rating was defined as the total of USS ratings recorded for all micturitions over the course of a day in the bladder diary. USS rating: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine. USS Sum rating per 24 hours was calculated as the mean rating scores on the USS multiplied by the mean number of micturitions per 24 hours at that visit.
Measured: Baseline, Week 4 and 12
Change From Baseline in International Prostate Symptom Score (IPSS) Total Score (Sum Question 1 [Q1] to Q7) Per 24 Hours at Week 4 and 12
The IPSS Total Score is obtained by combining the scores of the responses to 1 though 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.
Measured: Baseline, Week 4 and 12
Change From Baseline in IPSS Storage Domain (Sum Q2, Q4, and Q7) Per 24 Hours at Week 4 and 12
The IPSS Total Score is obtained by combining the scores of the responses to 1 though 7 component questions. Each question is scored from 0-5. Total IPSS range = 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Sum of Q2, Q4, and Q7 range = 0-15 points.
Measured: Baseline, Week 4 and 12
Change From Baseline in IPSS Voiding Domain (Sum Q1, Q3, Q5, and Q6) Per 24 Hours at Week 4 and 12
The IPSS Total Score is obtained by combining the scores of the responses to 1 though 7 component questions. Each question is scored from 0-5. Total IPSS range = 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Sum of Q1, Q3, Q5, and Q6 range = 0-20 points.
Measured: Baseline, Week 4 and 12
Change From Baseline in IPSS Quality of Life (QoL) Score (Q8) Per 24 Hours at Week 4 and 12
The IPSS Total Score is obtained by combining the scores of the responses to 1 though 7 component questions. Each question is scored from 0-5. Total IPSS range = 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Score of Q8 range = 0-5 points.
Measured: Baseline, Week 4 and 12
Change From Baseline in IPSS Individual Item Scores (Q1, Q2, Q3, Q4, Q5, Q6, and Q7) Per 24 Hours at Week 4
The IPSS Total Score is obtained by combining the scores of the responses to 1 though 7 component questions. Each question is scored from 0-5. Total IPSS range = 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.
Measured: Baseline, Week 4
Change From Baseline in IPSS Individual Item Scores (Q1, Q2,Q3, Q4, Q5, Q6, and Q7) Per 24 Hours at Week 12
The IPSS Total Score is obtained by combining the scores of the responses to 1 though 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.
Measured: Baseline, Week 12
Number of Participants With Change From Baseline in Patient Perception of Bladder Condition (PPBC) Per 24 Hours at Week 4
PPBC: self-administered, single-item, validated questionnaire. Rated on a 6-point scale: subject was asked: "Which of the following statements describes your bladder condition best at the moment?" 1=no problems at all; 2=some very minor problems; 3=some minor problems; 4=some moderate problems; 5=severe problems; 6=many severe problems. A post-baseline vs baseline variable with ordinal values was derived: 1=Deterioration=Difference in scores was positive; 2=No Change=Difference in scores was 0; 3=Minor Improvement=Difference in scores was -1; 4=Major Improvement=Difference in scores was ≤ 2.
Measured: Baseline, Week 4
Number of Participants With Change From Baseline in PPBC Per 24 Hours at Week 12
PPBC: self-administered, single-item, validated questionnaire. Rated on a 6-point scale: subject was asked: "Which of the following statements describes your bladder condition best at the moment?" 1=no problems at all; 2=some very minor problems; 3=some minor problems; 4=some moderate problems; 5=severe problems; 6=many severe problems. A post-baseline vs baseline variable with ordinal values was derived: 1=Deterioration=Difference in scores was positive; 2=No Change=Difference in scores was 0; 3=Minor Improvement=Difference in scores was -1; 4=Major Improvement=Difference in scores was ≤ 2.
Measured: Baseline, Week 12
Number of Participants With Change From Baseline in Urgency Perception Scale (UPS) Per 24 Hours at Week 4
Number of participants in 3-point category: improvement [>=1-point improvement]; no change; deterioration [>=1-point decrease], based on UPS score (rated on 3-point scale: 1=not able to hold urine; 3=able to finish what I am doing). Score change calculated as score at observation minus score at baseline; re-scaled to 3-point categorical variables.
Measured: Baseline, Week 4
Number of Participants With Change From Baseline in Change From Baseline in UPS Per 24 Hours at Week 12.
Number of participants in 3-point category: improvement [>=1-point improvement]; no change; deterioration [>=1-point decrease], based on UPS score (rated on 3-point scale: 1=not able to hold urine; 3=able to finish what I am doing). Score change calculated as score at observation minus score at baseline; re-scaled to 3-point categorical variables.
Measured: Baseline, Week 12
Change From Baseline in Overactive Bladder Questionnaire (OAB-q) Per 24 Hours at Week 4 and 12
OAB-q is a self-administered, 33-item, validated questionnaire that assesses how much the subject has been bothered by selected bladder symptoms during the previous week. Each item rated by subject on Likert scale 1 (least symptom bother) to 6 (most symptom bother). Raw scores were transformed to a score from 0-100. Once transformed, higher scores represent less favorable outcome.
Measured: Baseline, Week 4 and 12
Change From Baseline in Total Score of Each Health Related Quality of Life (HRQL) Domain of OAB-q at Week 4 and 12
HRQL domain and total raw score derived as sum of scores (6-point scale: 1 = not at all/none of the time; 6 = a very great deal/all of the time). Transformed score range 0 to 100 (Total HRQL or domain)=[(Highest possible raw score-Actual total raw score)/Raw score range]x100. Higher transformed scores indicative of better HRQL. Positive change in HRQL scores indicates improvement. Change: score at observation minus score at baseline.
Measured: Baseline, Week 4 and 12
Change From Baseline in Score of Each Health Related Quality of Life (HRQL) Domain of OAB-q at Week 4 and 12 (OAB-q Concern Domain)
The HRQL concern domain; range was 0-100. The transformed score for HRQL was calculated based on the following formula: Transformed score (HRQL) = [(Highest possible score - Actual raw score)/ Range]*100, where range was the raw score range. Positive change in HRQL Score indicates improvement.
Measured: Baseline, Week 4 and 12
Change From Baseline in Score of Each Health Related Quality of Life (HRQL) Domain of OAB-q at Week 4 and 12 (OAB-q Coping Domain)
The HRQL coping domain; range was 0-100. The transformed score for HRQL was calculated based on the following formula: Transformed score (HRQL) = [(Highest possible score - Actual raw score)/ Range]*100, where range was the raw score range. Positive change in HRQL Score indicates improvement.
Measured: Baseline, Week 4 and Week 12
Change From Baseline in Score of Each Health Related Quality of Life (HRQL) Domain of OAB-q at Week 4 and 12 (OAB-q Sleep Domain)
The HRQL sleep domain; range was 0-100. The transformed score for HRQL was calculated based on the following formula: Transformed score (HRQL) = [(Highest possible score - Actual raw score)/ Range]*100, where range was the raw score range. Positive change in HRQL Score indicates improvement.
Measured: Baseline, Week 4 and Week 12
Change From Baseline in Score of Each Health Related Quality of Life (HRQL) Domain of OAB-q at Week 4 and 12 (OAB-q Social Interaction Domain)
The HRQL social interaction domain; range was 0-100. The transformed score for HRQL was calculated based on the following formula: Transformed score (HRQL) = [(Highest possible score - Actual raw score)/ Range]*100, where range was the raw score range. Positive change in HRQL Score indicates improvement.
Measured: Baseline, Week 4 and Week 12
Change From Baseline in Post Void Residual (PVR) Urine Volume Per 24 Hours at Week 4, 8 and 12
Post-void residual volume measurement was measured by an ultrasound at Baseline, and at Weeks 4, 8 and 12.
Measured: Baseline, Week 4, 8 and 12
Change From Baseline in Maximum Urinary Flow Rate (QMAX) Per 24 Hours at Week 12
Maximum urinary flow rate (Qmax) was recorded at Baseline and Week 12 visit.
Measured: Baseline, Week 12
Number of Participants Reporting Urinary Retention Requiring Catheterization (All Causalities)
Number of participants experiencing serious and non-serious adverse events of acute urinary retention requiring catheterization.
Measured: Baseline, Week 12
Number of Participants Experiencing Adverse Events Related to Increased Voiding Difficulty (All Causalities)
Number of participants experiencing serious and non-serious adverse events related to increased voiding difficulty (ie, Dysuria, Urinary retention regardless of catheterization, Urine flow decreased, Residual urine volume, Residual urine volume increased, Residual urine, and Urinary hesitation)
Measured: Baseline, Week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Oct 2007 (estimated)
- Study startNov 2007
- Primary completionFeb 2009
- Study completionFeb 2009
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Overactive Bladder SyndromeStudies of the same condition, open and under way.
- More trials run by PfizerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 947 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pfizer
- Sponsor type
- Industry (pharma, biotech, devices)
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00546637
- Sponsor's protocol ID
- A0221009
- Status last verified
- Feb 2011
- First submitted
- 18 Oct 2007
- Last updated
- 18 Feb 2011
- Results posted
- Yes, on ClinicalTrials.gov
Study at a glance
From the registry record, last updated by the sponsor on 18 Feb 2011. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Fesoterodine As An "Add-On" Therapy In Men With Persistent Overactive Bladder Symptoms Under Monotherapy Of Alpha Blocker For Lower Urinary Tract Symptoms.
- ClinicalTrials.gov ID
- NCT00546637
- Acronym / sponsor ID
- A0221009
- Conditions
- Overactive Bladder Syndrome
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 947 participants (actual)
- Lead sponsor
- PfizerIndustry (pharma, biotech, devices)
- Study start
- Nov 2007
- Primary completion
- Feb 2009 (actual)
- Study completion
- Feb 2009 (actual)
- First posted
- 19 Oct 2007 (estimated)
- Results
- Posted 22 Nov 2010
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To evaluate the efficacy and safety of fesoterodine on overactive bladder symptom improvement when added to ongoing alpha blocker treatment.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Fesoterodine 4mg or 8mg | Experimental | Drug: Fesoterodine |
| Placebo | Placebo comparator | Drug: Placebo |
Who may qualify
- Ages
- 40 years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Men aged 40 years and above.
- On a stable and well-tolerated dose of an alpha-blocker prescribed for LUTS for at least 6 weeks prior to screening (Visit 1).
- Persistent symptoms of OAB with urinary frequency >=8 times/24 hours and micturition-related urgency episodes >=3 episode/24 hours.
Key exclusion criteria (3 listed)
- Contraindication to fesoterodine (antimuscarinics).
- Previous history of acute urinary retention requiring catheterization or severe voiding difficulties in the judgment of the investigator, prior to baseline.
- Unable to follow the study procedures, including completion of self-administered bladder diary and patient reported outcome questionnaires.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| FesoterodineFesoterodine 4mg or 8mg | Drug | Fesoterodine 4mg or 8mg |
| PlaceboPlacebo | Drug | Placebo |
Primary outcome
Numerical Change From Baseline in Micturition-Related Urgency Episodes Per 24 Hours at Week 12
Time frame: Baseline, Week 12
The mean number of micturition-related urgency episodes per 24 hours was calculated as the total number of micturitions with USS Scale >= 3 divided by the total number of days that diary data was collected at that visit. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.
33 secondary outcomes
Numerical Change From Baseline in Micturition-Related Urgency Episodes Per 24 Hours at Week 4
Time frame: Baseline, Week 4
Percentage Change From Baseline in Micturition-Related Urgency Episodes Per 24 Hours at Week 4 and 12
Time frame: Baseline, Week 4 and 12
Numerical Change From Baseline in Micturitions Per 24 Hours at Week 4 and 12
Time frame: Baseline, Week 4 and 12
Percentage Change From Baseline in Micturitions Per 24 Hours at Week 4 and 12
Time frame: Baseline, Week 4 and 12
Numerical Change From Baseline in Nocturnal Micturitions Per 24 Hours at Week 4 and 12
Time frame: Baseline, Week 4 and 12
Percentage Change From Baseline in Nocturnal Micturitions Per 24 Hours at Week 4 and 12
Time frame: Baseline, Week 4 and 12
Numerical Change From Baseline in Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 4 and 12
Time frame: Baseline, Week 4 and Week 12
Percentage Change From Baseline in UUI Episodes Per 24 Hours at Week 4 and 12
Time frame: Baseline, Week 4 and 12
Numerical Change From Baseline in Severe Micturition-Related Urgency Episodes Per 24 Hours at Week 4 and 12
Time frame: Baseline, Week 4 and 12
Percentage Change From Baseline in Severe Micturition-Related Urgency Episodes Per 24 Hours at Week 4 and 12
Time frame: Baseline, Week 4 and 12
Numerical Change From Baseline in Nocturnal Micturition-Related Urgency Episodes Per 24 Hours at Week 4 and 12
Time frame: Baseline, Week 4 and 12
Percentage Change From Baseline in Nocturnal Micturition-Related Urgency Episodes Per 24 Hours at Week 4 and 12
Time frame: Baseline, Week 4 and 12
Numerical Change From Baseline in Urinary Sensation Scale (USS) Sum Rating Per 24 Hours at Week 4 and 12
Time frame: Baseline, Week 4 and 12
Change From Baseline in International Prostate Symptom Score (IPSS) Total Score (Sum Question 1 [Q1] to Q7) Per 24 Hours at Week 4 and 12
Time frame: Baseline, Week 4 and 12
Change From Baseline in IPSS Storage Domain (Sum Q2, Q4, and Q7) Per 24 Hours at Week 4 and 12
Time frame: Baseline, Week 4 and 12
Change From Baseline in IPSS Voiding Domain (Sum Q1, Q3, Q5, and Q6) Per 24 Hours at Week 4 and 12
Time frame: Baseline, Week 4 and 12
Change From Baseline in IPSS Quality of Life (QoL) Score (Q8) Per 24 Hours at Week 4 and 12
Time frame: Baseline, Week 4 and 12
Change From Baseline in IPSS Individual Item Scores (Q1, Q2, Q3, Q4, Q5, Q6, and Q7) Per 24 Hours at Week 4
Time frame: Baseline, Week 4
Change From Baseline in IPSS Individual Item Scores (Q1, Q2,Q3, Q4, Q5, Q6, and Q7) Per 24 Hours at Week 12
Time frame: Baseline, Week 12
Number of Participants With Change From Baseline in Patient Perception of Bladder Condition (PPBC) Per 24 Hours at Week 4
Time frame: Baseline, Week 4
Number of Participants With Change From Baseline in PPBC Per 24 Hours at Week 12
Time frame: Baseline, Week 12
Number of Participants With Change From Baseline in Urgency Perception Scale (UPS) Per 24 Hours at Week 4
Time frame: Baseline, Week 4
Number of Participants With Change From Baseline in Change From Baseline in UPS Per 24 Hours at Week 12.
Time frame: Baseline, Week 12
Change From Baseline in Overactive Bladder Questionnaire (OAB-q) Per 24 Hours at Week 4 and 12
Time frame: Baseline, Week 4 and 12
Change From Baseline in Total Score of Each Health Related Quality of Life (HRQL) Domain of OAB-q at Week 4 and 12
Time frame: Baseline, Week 4 and 12
Change From Baseline in Score of Each Health Related Quality of Life (HRQL) Domain of OAB-q at Week 4 and 12 (OAB-q Concern Domain)
Time frame: Baseline, Week 4 and 12
Change From Baseline in Score of Each Health Related Quality of Life (HRQL) Domain of OAB-q at Week 4 and 12 (OAB-q Coping Domain)
Time frame: Baseline, Week 4 and Week 12
Change From Baseline in Score of Each Health Related Quality of Life (HRQL) Domain of OAB-q at Week 4 and 12 (OAB-q Sleep Domain)
Time frame: Baseline, Week 4 and Week 12
Change From Baseline in Score of Each Health Related Quality of Life (HRQL) Domain of OAB-q at Week 4 and 12 (OAB-q Social Interaction Domain)
Time frame: Baseline, Week 4 and Week 12
Change From Baseline in Post Void Residual (PVR) Urine Volume Per 24 Hours at Week 4, 8 and 12
Time frame: Baseline, Week 4, 8 and 12
Change From Baseline in Maximum Urinary Flow Rate (QMAX) Per 24 Hours at Week 12
Time frame: Baseline, Week 12
Number of Participants Reporting Urinary Retention Requiring Catheterization (All Causalities)
Time frame: Baseline, Week 12
Number of Participants Experiencing Adverse Events Related to Increased Voiding Difficulty (All Causalities)
Time frame: Baseline, Week 12
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Feb 2011.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
Related trials for Overactive Bladder Syndrome
Active, not recruitingPhase 2/3
Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms
Urinary Incontinence, Overactive Bladder Syndrome
Enrolling by invitationObservational study
Migraine Medication Effects on Urinary Symptoms
Overactive Bladder, Bladder Pain Syndrome
Recruiting
Tensi+ for Treating Overactive Bladder
Overactive Bladder (OAB)
Not yet recruitingObservational study
Efficacy and Safety of Peroneal Electric Transcutaneous Neuromodulation in the Real-world Clinical Practice
Overactive Bladder Syndrome
Recruiting
Improving Overactive Bladder Treatment Access and Adherence
Overactive Bladder Syndrome, Urinary Incontinence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pfizer CT.gov Call Center study director
Pfizer
137 sites in 19 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Fesoterodine in people with Overactive Bladder Syndrome, run by Pfizer at 137 sites in 19 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Feb 2011. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 137 sites in United States, Canada, Germany, Brazil, Philippines and 14 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 22 Nov 2010). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Numerical Change From Baseline in Micturition-Related Urgency Episodes Per 24 Hours at Week 12 (time frame: Baseline, Week 12). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Feb 2011.